Ladenburg Thalmann Financial Services’s Harvard Bioscience HBIO Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30	Closed	-$1K	–	4963
2017 Q2	$1K	Hold	30	–	–	﹤0.01%	4729
2017 Q1	$1K	Hold	30	–	–	﹤0.01%	4707
2016 Q4	$1K	Hold	30	–	–	﹤0.01%	4660
2016 Q3	$1K	Hold	30	–	–	﹤0.01%	4614
2016 Q2	$1K	Hold	30	–	–	﹤0.01%	4561
2016 Q1	$1K	Hold	30	–	–	﹤0.01%	4515
2015 Q4	$1K	Hold	30	–	–	﹤0.01%	4508
2015 Q3	$1K	Hold	30	–	–	﹤0.01%	4415
2015 Q2	$2K	Hold	30	–	–	﹤0.01%	4343
2015 Q1	$2K	Hold	30	–	–	﹤0.01%	4272
2014 Q4	$2K	Hold	30	–	–	﹤0.01%	4048
2014 Q3	$1K	Hold	30	–	–	﹤0.01%	3797
2014 Q2	$1K	Hold	30	–	–	﹤0.01%	3759
2014 Q1	$1K	Hold	30	–	–	﹤0.01%	3629
2013 Q4	$1K	Sell	30 -10	-25%	-$437	﹤0.01%	3620
2013 Q3	$2K	Hold	40	–	–	﹤0.01%	3446
2013 Q2	$1K	Buy	+40	New	+$1.53K	﹤0.01%	3466

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

Ladenburg Thalmann Financial Services's HBIO Position: Q3 2017 in Review

Ladenburg Thalmann Financial Services sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 30 shares — an estimated $1K sold.

Ladenburg Thalmann Financial Services first reported a position in HBIO in Q2 2013 and held it in 17 quarters. The position peaked at $2K in Q2 2015. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

Ladenburg Thalmann Financial Services reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 30 Harvard Bioscience shares in Q3 2017, an estimated $1K.
Ladenburg Thalmann Financial Services first reported a position in Harvard Bioscience in Q2 2013 and held it in 17 quarters.
Ladenburg Thalmann Financial Services's Harvard Bioscience position peaked at $2K in Q2 2015.
53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2017, filed 15 Nov 2017.